View Author
protein class antibody monkey iscom virus preparation vaccine envelope immunization clone antigen group challenge glycoprotein peptide response serum class i figure sivmac infection sequence b-lcl titre study ±iscom ratio measles protection presentation mv-f-iscom class ii molecules semipuri ®ed quil mv ±iscom preparations molecule rhesu 8789- presence number analysis dilution qa -3 qa -22 assay cytotoxic f-protein puri ®ed quil mv ±iscoms processing elisa group b experiment macaque envelope protein structure animal ii-restricted cleavage site component method immunodeficiency speci class i molecules envelope glycoproteins -22 result rhesus pbmc immunity pathway siv-mdp siv-iscom table nature 8672-20 iscom-like structures target epitope qa -3/22 mv ±iscom
5 Most Recent Publications
|
In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components.
(Article)
Stittelaar, K.J. Boes, J. Mulder, P.G.H. Spiekstra, A. Vries, P. de Roholl, P.J.M. Dalsgaard, K. Dobbelsteen, G.J.P.M. van den Alphen, L. van Osterhaus, A.D.M.E. Kersten, G.F.A. |
2000-05-01
|
|
Antigenicity and immunogenicity of recombinant envelope glycoproteins of SIVmac32H with different in vivo passage histories.
(Article)
Hulskotte, E.G.J. Rimmelzwaan, G.F. Boes, J. Bosch, M.L. Heeney, J.L. Norley, S.G. Vries, P. de Osterhaus, A.D.M.E. |
1995-01-01
|
|
Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines.
(Article)
Vries, P. de Heeney, J.L. Morein, B. Norley, S. Osterhaus, A.D.M.E. Boes, J. Dings, M.E.M. Hulskotte, E.G.J. Dubbes, R. Koornstra, W. Haaft, P. ten Akerblom, L. Eriksson, S. |
1994-11-11
|
|
Comparison of protection from homologous cell-free vs cell-associated SIV challenge afforded by inactivated whole SIV vaccines.
(Article)
Heeney, J.L. Vries, P. de Dubbes, R. Koornstra, W. Niphuis, H. Haaft, P. ten Boes, J. Dings, M.E.M. Morein, B. Osterhaus, A.D.M.E. |
1992-01-01
|
|
Measles virus transmembrane fusion protein synthesized de novo or presented in iscom is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition.
(Article)
Binnendijk, R.S. van Baalen, C.A. van Poelen, M.C.M. Vries, P. de Boes, J. Cerundolo, V. Osterhaus, A.D.M.E. Uytdehaag, F.G.C.M. |
1992-01-01
|
